Margaret Rosenfeld, MD, MPH, Seattle Children’s Research Institute and Department of Pediatrics, University of Washington School of Medicine

Margaret Rosenfeld, MD, MPH, Seattle Children’s Research Institute and Department of Pediatrics, University of Washington School of Medicine

Dr. Rosenfeld was a lead investigator in the Phase 3 ARRIVAL study, sponsored by Vertex, which found Ivacaftor (KALYDECO®) is generally safe and effective in patients aged 2 years and older who have cystic fibrosis and specific CFTR mutations. Dr. Rosenfeld noted...

Pin It on Pinterest